0001209191-18-016686.txt : 20180305 0001209191-18-016686.hdr.sgml : 20180305 20180305173241 ACCESSION NUMBER: 0001209191-18-016686 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180301 FILED AS OF DATE: 20180305 DATE AS OF CHANGE: 20180305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gilmartin Geoffrey S. CENTRAL INDEX KEY: 0001688268 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 18667586 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Gilmartin Greffrey S. DATE OF NAME CHANGE: 20161024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-225-0096 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-01 0 0001445283 PROTEOSTASIS THERAPEUTICS, INC. PTI 0001688268 Gilmartin Geoffrey S. C/O PROTEOSTASIS THERAPEUTICS, INC. 200 TECHNOLOGY SQUARE, 4TH FLOOR CAMBRIDGE MA 02139 0 1 0 0 Chief Development Officer Employee Stock Option (Right to Buy) 3.11 2018-03-01 4 A 0 29900 0.00 A 2028-03-01 Common Stock 29900 29900 D These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on February 1, 2019, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on February 1, 2022, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities. /s/ Janet L. Smart, Attorney-in-Fact 2018-03-05